FDA granted accelerated approval to Enhertu for the treatment of adults with unresectable or metastatic HER2-positive breast cancer
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer…
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer…
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes…
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes…
In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in…
Register for Cleveland Clinic’s 8th Annual Cleveland Breast Cancer Summit: Collaborating for a Cure, Friday August 9, 2024 LIVE at the Intercontinental Hotel & Conference…
Taletrectinib, an experimental oral next-generation tyrosine kinase inhibitor (TKI), has demonstrated robust clinical activity in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
Listen as Dr. Kim explains how the model uses common clinical variables to flag high-risk patients who may benefit from endoscopic screening.
The advent of next-generation antibody-drug conjugates (ADCs), particularly trastuzumab deruxtecan (T-DXd), has transformed our understanding of human epidermal growth factor receptor 2 (HER2) targetability for…
